and will enter an increasingly competitive market in which Roche has been setting the pace recently with Ocrevus (ocrelizumab), an anti-CD20 drug which has already become a blockbuster following ...

Roche has filed for approval in the US for BCL-2 inhibitor Venclexta (venetoclax) plus its anti-CD20 drug Gazyva (obinutuzumab) for patients with previously untreated CLL with co-existing medical ...

The findings reinforce the potential of BRIUMVI in improving patient outcomes for those seeking an alternative to their previous anti-CD20 therapy. Furthermore, the article in CNS DRUGS offers an ...